



Janine Quinter

Medizinische Onkologie und Hämatologie · Dept. I

Contact

Janine Quinter
St. Gallen

T +41 71 494 1099
Janine.Quinter@h-och.ch

Units

Medizinische Onkologie und Hämatologie

Publications (0)

No results found.

Projects (82)

A Phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors, followed by an expansion part to assess safety and preliminary anti-tumor activity

Clinical Studies - Dec 20, 2024 - Dec 31, 2099

Ongoing

Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial.

Clinical Studies - Oct 31, 2024 - Dec 31, 2099

Ongoing

A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy

Clinical Studies - Oct 7, 2024 - Dec 31, 2099

Ongoing

A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors

Clinical Studies - Aug 27, 2024 - Dec 31, 2099

Ongoing

A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

Clinical Studies - Aug 16, 2024 - Dec 31, 2099

Ongoing

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08) (Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)

Clinical Studies - Aug 13, 2024 - Dec 31, 2099

Ongoing

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)

Clinical Studies - Apr 18, 2024 - Dec 31, 2099

Ongoing

Liquid biopsy to diagnose and monitor central nervous system (CNS) involvement in high-risk B cell non-Hodgkin lymphoma

Clinical Studies - Apr 10, 2024 - Dec 31, 2099

Ongoing

An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors

Clinical Studies - Mar 28, 2024 - Dec 31, 2099

Ongoing

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)

Clinical Studies - Jan 26, 2024 - Dec 31, 2099

Ongoing

A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer.

Clinical Studies - Dec 21, 2023 - Dec 31, 2027

Ongoing

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Clinical Studies - Nov 17, 2023 - Dec 31, 2099

Ongoing

A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy

Clinical Studies - Nov 3, 2023 - Dec 31, 2099

Ongoing

A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Clinical Studies - Oct 30, 2023 - Dec 31, 2099

Ongoing

A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents

Clinical Studies - Oct 18, 2023 - Dec 31, 2099

Ongoing

A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects with Relapsed Small Cell Lung Cancer After Platinum-based First Line chemotherapy (DeLLphi-304)

Clinical Studies - Jul 17, 2023 - Dec 31, 2099

Ongoing

Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA

Clinical Studies - Apr 26, 2023 - Dec 31, 2099

Ongoing

A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI

Clinical Studies - Mar 14, 2023 - Dec 31, 2099

Ongoing

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Mono-therapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours (TROPION-PanTumor03)

Clinical Studies - Mar 2, 2023 - Oct 2, 2023

Completed

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

Clinical Studies - Feb 7, 2023 - Dec 31, 2099

Ongoing

A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-6598 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Clinical Studies - Feb 1, 2023 - Dec 31, 2099

Ongoing

A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors

Clinical Studies - Jan 11, 2023 - Dec 31, 2099

Ongoing

CA209-6K7 - Intrathecal administration of anti-PD1/anti-CTLA-4 in combination with systemic combination of anti-PD1/anti-CTLA-4 in patients with NSCLC without oncogenic driver mutation or melanoma and newly diagnosed leptomeningeal metastasis: a multicentric phase I study

Clinical Studies - Dec 9, 2022 - Dec 31, 2099

Ongoing

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-resistant Prostate Cancer

Clinical Studies - Nov 30, 2022 - Dec 31, 2099

Ongoing

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1

Clinical Studies - Nov 28, 2022 - Dec 31, 2099

Ongoing

IP-001_RFA (IP-IIO-622): Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter Phase 1b/2a trial in colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma patients

Clinical Studies - Nov 8, 2022 - Dec 31, 2099

Ongoing

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Clinical Studies - Sep 16, 2022 - Dec 31, 2099

Ongoing

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1

Clinical Studies - Sep 9, 2022 - Dec 31, 2099

Ongoing

CATALYM CTL-002-001 A PHASE 1/2, FIRST-IN-HUMAN, TWO-PART, OPEN-LABEL CLINICAL TRIAL OF INTRAVENOUS ADMINISTRATION OF CTL-002 GIVEN AS MONOTHERAPY AND/OR IN COMBINATION WITH AN ANTI-PD-1 CHECKPOINT INHIBITOR IN SUBJECTS WITH ADVANCED-STAGE, RELAPSED/REFRACTORY SOLID TUMORS

Clinical Studies - Sep 2, 2022 - Dec 31, 2099

Ongoing

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

Clinical Studies - Aug 9, 2022 - Dec 31, 2099

Ongoing

Phase 1/Phase 2 Studie zur Beurteilung der Sicherheit und Verträglichkeit von MK-1088 als Monotherapie und in Kombination mit Pembrolizumab bei Teilnehmenden mit fortgeschrittenen soliden Tumoren

Clinical Studies - Jul 8, 2022 - Aug 13, 2024

Completed

ANV419 Single Agent (Parts A-C) or Combination (Part D) First in Human Study Phase 1/2: Open-label, Dose Escalation and Expansion Study in Patients with Relapsed/Refractory Advanced Solid Tumors and Multiple Myeloma. (Anaveon)

Clinical Studies - Mar 3, 2022 - Mar 2, 2024

Completed

A Phase III, randomised, Open-Label, multicenter study evaluating the efficacy and safety of adjuvant GDC-9545 compared with physician's choice of adjuvant endocrine Monotherapy in patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

Clinical Studies - Mar 1, 2022 - Dec 31, 2099

Ongoing

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors

Clinical Studies - Jan 13, 2022 - Dec 31, 2099

Ongoing

A phase 3 multicenter, randomized, prospective, open-label trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukemia (CLL)

Clinical Studies - Dec 16, 2021 - Dec 31, 2099

Ongoing

A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy

Clinical Studies - Oct 13, 2021 - Dec 31, 2099

Ongoing

DS1062-A-U303 (TROPION-lung07) A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations TROPION-Lung07

Clinical Studies - Oct 8, 2021 - Dec 31, 2099

Ongoing

in Subjects with Methylthioadenosine

Clinical Studies - Oct 8, 2021 - Jan 8, 2025

Completed

Randomisierte Phase-3-Studie mit DS-1062a im Vergleich zu Docetaxel bei zuvor behandeltem fortgeschrittenem oder metastasiertem nicht-kleinzelligem Lungenkrebs ohne verwertbare genomische Veränderungen (TROPION-Lung01)

Clinical Studies - Oct 8, 2021 - Oct 27, 2099

Ongoing

A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98)

Clinical Studies - Oct 1, 2021 - Dec 31, 2099

Ongoing

A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer(KEYNOTE-B99)

Clinical Studies - Sep 29, 2021 - Jan 12, 2024

Completed

SAKK 15/19 Thoracic radiotherapy plus maintenance Durvalumab after first line Carboplatin and Etoposide plus Durvalumab in extensive-stage disease small cell lung cancer (EDSCLC) A multicenter single arm open label phase II trial

Clinical Studies - Jul 14, 2021 - Dec 31, 2022

Ongoing

Assessing a ctDNA and PET-oriented therapy in patients with DLBCL multicenter, open-label, phase II trial

Clinical Studies - Jun 8, 2021 - Dec 31, 2022

Ongoing

SAKK 67/20 Open-label single-stage phase 1B study of the new micellar docetaxel compound Docecal in patients with advanced castration-resistant prostate cancer

Clinical Studies - May 28, 2021 - Feb 1, 2024

Completed

ON-TRK: Prospective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib

Clinical Studies - Apr 14, 2021 - Dec 31, 2022

Ongoing

A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)

Clinical Studies - Mar 17, 2021 - Nov 5, 2024

Completed

SAKK 17/18 Origin

Clinical Studies - Mar 8, 2021 - Sep 26, 2024

Completed

Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer- a randomized Phase III trial An ENGOT Trial

Clinical Studies - Mar 4, 2021 - Dec 31, 2022

Ongoing

A Phase II, Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Neoadjuvant And Adjuvant Tiragolumab Plus Atezolizumab, With Or Without Platinum-Based Chemotherapy, In Patients With Previously Untreated Locally Advanced Resectable Stage II, Ila, Or Select IIlb Non-Small Cell Lung Cancer

Clinical Studies - Feb 12, 2021 - Dec 31, 2099

Ongoing

A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse

Clinical Studies - Oct 28, 2020 - Jul 3, 2024

Completed

Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter phase Ib/Ila trial with expansion cohorts in melanoma and soft tissue sarcoma patients

Clinical Studies - Oct 7, 2020 - Dec 31, 2099

Ongoing

Vacuum assisted biopsy Immediately before Surgery as an Intra- or pre-Operative surrogate for patient response to Neoadjuvant chemotherapy for breast cancer (VISION I) A multicenter prospective feasibility trial

Clinical Studies - Aug 11, 2020 - Dec 31, 2099

Ongoing

A randomised non-comparative open label phase II trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed, in EGFR-mutant non-small cell lung carcinoma with acquired resistance ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant non-small cell lung carcinoma

Clinical Studies - Jul 22, 2020 - Aug 30, 2028

Completed

VerVe: Observational study of the use of venetoclax in patients with chronic lymphocytic leukemia (CLL) under real-life setting in Austria, Germany and Switzerland (Venetoclax Real Value)

Clinical Studies - Jul 15, 2020 - Sep 27, 2022

Automatically Closed

A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Clinical Studies - Jul 10, 2020 - Mar 11, 2024

Completed

A Multicenter Phase III Randomized study with second line chemotherapy plus or minus Bevacizumab in patients with Platinum sensitive Epithelial ovarian cancer recurrence after a Bevacizumab/chemotherapy first line. MITO-16b, MANGO-OV2b

Clinical Studies - Jul 9, 2020 - Jun 21, 2023

Completed

A Phase III, randomized, double-blinded, placebo-controlled study of Tiragolumab, an Anti-Tigit Antibody, in combination with Atezolizumab compared with placebo in combination with Atezolizumab in patients with previously untreated locally advanced unresectable or metastatic PD-L1 selected Non-Small Cell Lung Cancer

Clinical Studies - Jun 11, 2020 - Dec 31, 2099

Ongoing

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

Clinical Studies - Mar 3, 2020 - Dec 23, 2024

Completed

A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.

Clinical Studies - Dec 18, 2019 - Dec 31, 2099

Ongoing

A 24 weeks activity program in patients with early breast cancer receiving aromatase inhibitor therapy. A multicenter randomized phase III trial.

Clinical Studies - Jun 17, 2019 - Jun 21, 2023

Completed

Randomized Phase II Trial on fitness and comorbidity-tailored treatment in elderly patients with newly diagnosed primary CNS Lymphoma (FIORELLA Trial)

Clinical Studies - Jun 7, 2019 - Dec 31, 2099

Ongoing

ENIGMA: Open label, non-randomized, Phase IB study to characterize safety, tolerability and recommended dose of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic melanoma

Clinical Studies - May 2, 2019 - Dec 31, 2024

Automatically Closed

Peace-4

Clinical Studies - Apr 26, 2019 - Dec 31, 2099

Ongoing

A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-dose Therapy

Clinical Studies - Apr 18, 2019 - Dec 31, 2025

Ongoing

IBCSG 55-17 "Touch" Phase II open-label, multicenter, randomized trial of neo-adjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer

Clinical Studies - Dec 4, 2018 - Jun 7, 2023

Completed

Open-label, non-randomized phase-1 study of liposomal doxorubicin TLD-1 in patients with advanced solid tumors

Clinical Studies - Oct 26, 2018 - Dec 22, 2023

Completed

Trial SAKK 19/17: First line durvalumab in patients with PD-L1 positive, advanced NSCLC with performance status 2 unsuitable for combination chemotherapy. A multicenter, single-arm phase II trial

Clinical Studies - Oct 23, 2018 - Dec 31, 2019

Ongoing

ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with one novel hormonal agent first line and non-progressive disease after second line treatment with a taxane: A multicenter randomized double-blind placebo-controlled phase II trial

Clinical Studies - Mar 31, 2017 - Jun 6, 2024

Completed

SAKK GRAALL 2014: Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)

Clinical Studies - Jun 3, 2016 - Dec 31, 2019

Ongoing

Investigation of Metformin in patients with castration resistant Prostate Cancer in combination with Enzalutamide vs. Enzalutamide alone (IMPROVE TRIAL)

Clinical Studies - May 20, 2016 - Feb 15, 2023

Completed

Anti-PD-L1 antibody MEDI4736 in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.

Clinical Studies - Apr 22, 2016 - Aug 28, 2024

Completed

A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III

Clinical Studies - Oct 26, 2015 - Dec 31, 2019

Ongoing

Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score > 4.5)

Clinical Studies - May 5, 2015 - Dec 31, 2099

Ongoing

Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE)

Clinical Studies - Aug 7, 2014 - Dec 31, 2099

Ongoing

Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS \geq 1.5)

Clinical Studies - Sep 28, 2013 - Dec 1, 2023

Completed

Therapieoptimierungsstudie in der Primärtherapie des intermediären Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET

Clinical Studies - Apr 16, 2013 - Aug 30, 2023

Completed

Qualitätssicherungsprotokoll zur Toxizitätsreduktion in der Primärtherapie des frühen Morbus Hodgkin (2x ABVD+IF vs 2x AVD+IF)

Clinical Studies - Dec 30, 2009 - Jun 26, 2024

Completed

Qualitätssicherungsprotokoll zur Effektivitätssteigerung in der Primärtherapie des intermediären Morbus Hodgkin (4x ABVD+IF vs 2x BEACOPP eskaliert + 2x ABVD+IF)

Clinical Studies - Dec 30, 2009 - Jun 26, 2024

Completed

A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer (STP)

Clinical Studies - Sep 3, 2009 - Dec 31, 2099

Ongoing

A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer

Clinical Studies - Sep 3, 2009 - Dec 31, 2099

Ongoing

Eine Substudie zur TEXT-Studie zur Untersuchung der Knochendichte und Analyse von Knochenmarkern und Wachstumsfaktoren Substudie zur Studie zu Tamoxifen und Exemestan (IBCSG 25-02 / BIG 3-02 TEXT)

Clinical Studies - Sep 3, 2009 - Dec 31, 2009

Ongoing

Randomized induction and post induction therapy in adult patients (≤ yrof age) with acute myelocytic leukaemia (AML) of refractory anemia with excess of blasts (RAEB, RAEB-t) with IPSS score ≥ 1.5

Clinical Studies - Aug 18, 2000 - Feb 26, 2021

Completed

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch